KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Change in Acquisitions & Divestments (2021 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Change in Acquisitions & Divestments for 5 consecutive years, with $145.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Acquisitions & Divestments rose 17.25% year-over-year to $145.3 million, compared with a TTM value of $494.1 million through Dec 2025, down 15.59%, and an annual FY2025 reading of $494.1 million, down 15.59% over the prior year.
  • Change in Acquisitions & Divestments was $145.3 million for Q4 2025 at Aurinia Pharmaceuticals, up from $93.5 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $170.5 million in Q1 2024 and bottomed at $60.9 million in Q1 2021.
  • Average Change in Acquisitions & Divestments over 5 years is $121.4 million, with a median of $120.5 million recorded in 2022.
  • The sharpest move saw Change in Acquisitions & Divestments surged 81.43% in 2022, then decreased 29.47% in 2025.
  • Year by year, Change in Acquisitions & Divestments stood at $90.7 million in 2021, then surged by 30.36% to $118.2 million in 2022, then increased by 16.82% to $138.1 million in 2023, then fell by 10.22% to $124.0 million in 2024, then grew by 17.25% to $145.3 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for AUPH at $145.3 million in Q4 2025, $93.5 million in Q3 2025, and $132.2 million in Q2 2025.